GENEA BIOMEDX UK LIMITED
Get an alert when GENEA BIOMEDX UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£158K
-68.5% lowest in 6 filed years
Net assets
-£6.2M
+28.8% highest in 6 filed years
Employees
5
-37.5% lowest in 6 filed years
Profit before tax
£2.5M
+608.3% highest in 6 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Annual accounts overdue
Due 2025-09-30.
-
Audit opinion: Qualified
Latest auditor's report carried a non-clean opinion.
-
Negative shareholders' funds
Net assets
6-year trend · vs Industrials median
Accounts
6-year trend · Δ = latest vs prior filed period · latest reflected 2023-12-31
| Metric | Trend | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2021-12-31 | 2022-12-31 | 2023-12-31 | Δ vs prior |
|---|---|---|---|---|---|---|---|---|
| Turnover | £6,893,356 | £5,978,544 | £5,074,427 | £2,991,264 | £6,413,368 | £3,245,659 | -49.4% | |
| Operating profit | -£848,990 | -£933,106 | -£708,472 | -£371,435 | -£499,705 | £887,523 | +277.6% | |
| Profit before tax | -£847,393 | -£929,014 | -£703,667 | -£369,009 | -£494,785 | £2,515,232 | +608.3% | |
| Net profit | — | — | — | — | -£494,729 | £2,515,232 | +608.4% | |
| Cash | £204,646 | £1,090,027 | £316,365 | £825,472 | £503,205 | £158,312 | -68.5% | |
| Total assets less current liabilities | -£6,022,786 | -£6,952,303 | -£7,803,470 | -£8,172,479 | -£8,667,208 | -£6,151,976 | +29% | |
| Net assets | -£6,282,736 | -£7,223,503 | -£7,911,401 | -£8,241,713 | -£8,736,442 | -£6,221,210 | +28.8% | |
| Equity | -£6,282,736 | -£7,223,503 | -£7,911,401 | -£8,241,713 | — | — | — | |
| Average employees | 12 | 12 | 12 | 11 | 8 | 5 | -37.5% | |
| Wages | — | — | — | — | — | — | — | |
| Directors' remuneration | — | — | — | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|---|
| Operating margin | -12.3% | -15.6% | -14.0% | -12.4% | -7.8% | 27.3% | |
| Net margin | — | — | — | — | -7.7% | 77.5% | |
| Gearing (liabilities / total assets) | — | — | — | — | 378.5% | 524.5% | |
| Current ratio | — | — | — | — | 0.26x | 0.19x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- GENEA BIOMEDX UK LIMITED 2013-08-07 → present
- GENEA BIOPLATFORMS UK LIMITED 2012-11-30 → 2013-08-07
Audit & accounting basis
- Accounting basis
- FRS 102 §1A
- Reporting scope
- Standalone (parent only)
- Abridged
- Yes — abridged accounts (limited disclosure)
- Auditor
- Kreston Reeves Audit LLP
- Audit opinion
- Qualified
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
1 active · 9 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHENG, Ka King | Director | 2024-10-18 | Oct 1967 | Hong Konger |
Show 9 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| WEAVER, Mary | Secretary | 2015-02-11 | 2016-02-26 |
| BRENNAN, Christopher David | Director | 2012-11-30 | 2015-11-26 |
| CHENG, Ka King | Director | 2022-09-30 | 2023-06-21 |
| GRANEY, Susan Rose | Director | 2015-12-01 | 2022-09-30 |
| HON, Hoi Kwong | Director | 2022-09-30 | 2023-06-21 |
| LANCKEN, Bradley Peter | Director | 2022-09-30 | 2023-06-21 |
| LIANG, Bo, Dr | Director | 2023-06-22 | 2024-10-18 |
| LOW, Andrew Donald | Director | 2022-09-30 | 2023-06-23 |
| STOJANOV, Tomas | Director | 2012-11-30 | 2022-09-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Dr Bo Liang | Individual | Shares 25–50% | 2023-06-21 | Active |
| Genea Biomedx Pty Ltd | Corporate entity | Shares 75–100% | 2022-09-01 | Active |
| We Doctor Holdings Limited | Corporate entity | Shares 50–75%, Voting 50–75%, Appoints directors | 2022-07-01 | Ceased 2022-09-01 |
| Mr Kam Ching Ng | Individual | Shares 25–50% | 2018-12-27 | Ceased 2021-07-01 |
Filing timeline
Last 20 of 70 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-19 | AA | accounts | Accounts with accounts type full | |
| 2026-01-08 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-12-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-18 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-18 | TM01 | officers | Termination director company with name termination date | |
| 2024-09-05 | AA | accounts | Accounts with accounts type full | |
| 2024-03-22 | AA | accounts | Accounts with accounts type full | |
| 2023-12-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-12-14 | PSC01 | persons-with-significant-control | Notification of a person with significant control | |
| 2023-09-26 | DISS40 | gazette | Gazette filings brought up to date | |
| 2023-09-18 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-18 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-18 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-18 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-11 | AP01 | officers | Appoint person director company with name date | |
| 2023-08-29 | GAZ1 | gazette | Gazette notice compulsory | |
| 2023-03-29 | AA01 | accounts | Change account reference date company current shortened | |
| 2023-02-28 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2022-12-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-12-13 | PSC02 | persons-with-significant-control | Notification of a person with significant control |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.